Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2009 - 2025)

Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization history runs 17 years deep, the most recent figure standing at $543.7 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization rose 53.54% year-over-year to $543.7 million; the TTM figure through Dec 2025 stood at $543.7 million (up 53.54% YoY), while the FY2025 annual figure was $543.7 million, up 53.54% from the prior year.
• Accumulated Depreciation & Amortization was $543.7 million for Q4 2025 at Regeneron Pharmaceuticals, up from $354.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $543.7 million in Q4 2025 to a low of $281.1 million in Q4 2021.
• Historically, Accumulated Depreciation & Amortization has averaged $362.3 million across 5 years, with a median of $328.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accumulated Depreciation & Amortization grew 7.69% in 2024, then surged 53.54% in 2025.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $281.1 million in 2021, then rose by 8.11% to $303.9 million in 2022, then climbed by 8.19% to $328.8 million in 2023, then increased by 7.69% to $354.1 million in 2024, then surged by 53.54% to $543.7 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $543.7 million (Q4 2025), $354.1 million (Q4 2024), and $328.8 million (Q4 2023), per Business Quant data.